<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849145</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2014-06 ctDNA R0</org_study_id>
    <nct_id>NCT02849145</nct_id>
  </id_info>
  <brief_title>Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)</brief_title>
  <official_title>Study to Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (R0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate&#xD;
      in the blood, before and after curative resection of hepatic metastasis of uveal melanoma&#xD;
      (HMUM) and during post-surgery follow-up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ct DNA R0 study is a prospective, open labelled, monocentric trial. The aim is to&#xD;
      evaluate the circulating tumor DNA rate in the blood, before and after curative resection of&#xD;
      hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up.&#xD;
&#xD;
      The patient will have a blood sample before and after the surgery and during the post-surgery&#xD;
      follow-up. The patient will have a maximum of 10 blood samples during the 2 years of his&#xD;
      follow-up of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the circulating tumor DNA rate before/after surgery and the rate of effective complete resection</measure>
    <time_frame>Up to one month</time_frame>
    <description>Comparison the circulating tumor DNA rate before/after surgery and the rate of effective complete resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stability of the circulating tumor DNA on 2 pre-surgery samples</measure>
    <time_frame>Up to one month</time_frame>
    <description>Comparison the circulating tumor DNA rate before/after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of the correlation between the variation rate of the circulating tumor DNA at different points (T0, T1, T2, T3, T4 and Tn) and the apparition time of metastasis on hepatic MRI during the study follow-up.</measure>
    <time_frame>two years</time_frame>
    <description>Timepoints :&#xD;
T0 and T1 : before surgery T2 : 2 days after surgery T3 : 8 days after surgery T4 to T9 : every 4 months up to two years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of GNA11 or GNAQ mutation on one of the hepatic metastasis</measure>
    <time_frame>Up to one month</time_frame>
    <description>Search of GNA 11 or GNAQ mutation by Next Generation Sequencing techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative study of the mutation profile of the ocular tumor if available, resected hepatic metastasis.</measure>
    <time_frame>Up to one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological study of the resected hepatic metastasis (inflammation, Ki 67, necrosis, fibrosis and vascularization, genomic analysis of the metastasis)</measure>
    <time_frame>Up to one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of genetic factors for uveal melanoma</measure>
    <time_frame>Up to one month</time_frame>
    <description>Search of genetic factors for uveal melanoma to be used as predictive evidence of the clinical response for possible future treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of overall survival after HMUM resection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Biological/Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>7,5 ml of patient peripherical blood will be collected at each blood sample.</description>
    <arm_group_label>Biological/Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years old or more&#xD;
&#xD;
          2. Patient with hepatic injury of metastatic uveal melanoma eligible for curative surgery&#xD;
             (R0).&#xD;
&#xD;
          3. No other distant metastasis (CT thoracic -abdomino -pelvic, bone scan).Measurable&#xD;
             metastatic disease (echography, CT and/or MRI, FDG-PET, (fluoro- D-glucose integrated&#xD;
             with computed tomography)).&#xD;
&#xD;
          4. Patient able to stand a blood collection.&#xD;
&#xD;
          5. Patient explanation given and consent information signed or by legal representative.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          6. Patient without social protection / insurance..&#xD;
&#xD;
          7. Patient with hepatic metastasis unresectable by surgery&#xD;
&#xD;
          8. Patient with extra-hepatic metastasis.&#xD;
&#xD;
          9. Person deprived of liberty or under guardianship&#xD;
&#xD;
         10. Inability to submit to medical monitoring of the trial for reasons of geography,&#xD;
             social or psychological.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Mariani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

